OncoSynergy, Inc.
- Biotech or pharma, therapeutic R&D
A physician-led, clinical-stage immuno-oncology company whose mission is to dramatically improve outcomes for patients suffering from the worst cancers by targeting the tumor microenvironment. Our first-in-class therapeutic, OS2966, targets the key receptor that modulates communication between the tumor and its microenvironment, cutting off cancers' life lines. OS2966 has been de-risked in a first-in-human trial demonstrating excellent safety. In addition, our portfolio includes, OS9455, a bio-better anti-PD1 therapeutic which has demonstrated improved pre-clinical efficacy and stability versus gold standard checkpoint inhibitors.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}